Evidence map›Paper›PMID 26351278›Full record

ArticleInfection and immunity2015

Nonredundant Roles of Interleukin-17A (IL-17A) and IL-22 in Murine Host Defense against Cutaneous and Hematogenous Infection Due to Methicillin-Resistant Staphylococcus aureus.

Liana C Chan, Siyang Chaili, Scott G Filler, Kevin Barr, Huiyuan Wang, Deborah Kupferwasser, John E Edwards, Yan Q Xiong, Ashraf S Ibrahim, Lloyd S Miller and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 58 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Kidney-resident innate-like memory γδ T cells control chronicProceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Immune Response to Persistent Staphyloccocus Aureus Periprosthetic Joint Infection in a Mouse Tibial Implant Model.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  10. International journal of molecular sciences · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Role of Interleukin-33 inFrontiers in immunology · 2020
    Article
  16. Article
  17. Review
  18. Risk stratification biomarkers forClinical & translational immunology · 2020
    Article
  19. Article
  20. Clonal Vγ6Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Liana C ChanDivision of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Siyang ChailiDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Scott G FillerDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Kevin BarrDivision of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
Huiyuan WangDivision of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
Deborah KupferwasserDivision of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA.
John E EdwardsDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Yan Q XiongDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Ashraf S IbrahimDivision of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Lloyd S MillerDepartment of Dermatology, Johns Hopkins University, Baltimore, Maryland, USA.
Clint S SchmidtNovaDigm Therapeutics, Inc., Grand Forks, North Dakota, USA.
John P HennesseyNovaDigm Therapeutics, Inc., Grand Forks, North Dakota, USA.
Michael R YeamanDivision of Molecular Medicine, Harbor-UCLA Medical Center, Torrance, California, USA Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA St. John's Cardiovascular Research Center, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA MRYeaman@ucla.edu.
Harbor–UCLA Medical Center · USUCLA Medical Center · USNovaDigm Therapeutics (United States) · USThe Lundquist Institute · USJohns Hopkins University · US

Funding

Vaccine Strategies for Disseminated CandidiasisR01AI063382 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI EDWARDS, JOHN E · 2006 to 2017
$3.0M
Mitigating Resistance & Virulence in MRSAR33AI111661 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2016 to 2018
$1.2M
Mitigating Resistance & Virulence in MRSAR21AI111661 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI YEAMAN, MICHAEL R · 2014 to 2015
$378k
STAT3 and IL-17-Th17 in skin immunity to MRSAR56AR065804 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MILLER, LLOYD S · 2014 to 2014
$356k
NIAID NIH HHS AI-063382NIAID NIH HHS AI-111661NIAID NIH HHS R01 AI063382NIAID NIH HHS R21 AI111661NIAID NIH HHS R33 AI111661NIAMS NIH HHS AR-065804NIAMS NIH HHS R56 AR065804
6 · The paper itself

Abstract

Staphylococcus aureus is the leading cause of skin and skin structure infections (SSSI) in humans. Moreover, the high frequency of recurring SSSI due to S. aureus, particularly methicillin-resistant S. aureus (MRSA) strains, suggests that infection induces suboptimal anamnestic defenses. The present study addresses the hypothesis that interleukin-17A (IL-17A) and IL-22 play distinct roles in immunity to cutaneous and invasive MRSA infection in a mouse model of SSSI. Mice were treated with specific neutralizing antibodies against IL-17A and/or IL-22 and infected with MRSA, after which the severity of infection and host immune response were determined. Neutralization of either IL-17A or IL-22 reduced T cell and neutrophil infiltration and host defense peptide elaboration in lesions. These events corresponded with increased abscess severity, MRSA viability, and CFU density in skin. Interestingly, combined inhibition of IL-17A and IL-22 did not worsen abscesses but did increase gamma interferon (IFN-γ) expression at these sites. The inhibition of IL-22 led to a reduction in IL-17A expression, but not vice versa. These results suggest that the expression of IL-17A is at least partially dependent on IL-22 in this model. Inhibition of IL-17A but not IL-22 led to hematogenous dissemination to kidneys, which correlated with decreased T cell infiltration in renal tissue. Collectively, these findings indicate that IL-17A and IL-22 have complementary but nonredundant roles in host defense against cutaneous versus hematogenous infection. These insights may support targeted immune enhancement or other novel approaches to address the challenge of MRSA infection.

Indexed as

AnimalsHematologic DiseasesHumansInterleukin-17Interleukin-22InterleukinsMaleMethicillin-Resistant Staphylococcus aureusMiceMice, Inbred BALB CMice, Inbred C57BLStaphylococcal Skin InfectionsInterleukin-17Interleukin-22Interleukins

Identifiers

PMID26351278
PMCPMC4598415
OpenAlexW1559033008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.